350 related articles for article (PubMed ID: 29719441)
1. Aromatase inhibitors in premenopausal women with breast cancer: the state of the art and future prospects.
Pistelli M; Mora AD; Ballatore Z; Berardi R
Curr Oncol; 2018 Apr; 25(2):e168-e175. PubMed ID: 29719441
[TBL] [Abstract][Full Text] [Related]
2. The breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors.
Rugo HS
Ann Oncol; 2008 Jan; 19(1):16-27. PubMed ID: 17693420
[TBL] [Abstract][Full Text] [Related]
3. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.
Gibson LJ; Dawson C; Lawrence DH; Bliss JM
Cochrane Database Syst Rev; 2007 Jan; (1):CD003370. PubMed ID: 17253488
[TBL] [Abstract][Full Text] [Related]
4. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
Berry J
Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
[TBL] [Abstract][Full Text] [Related]
5. The aromatase inhibitors (plus ovarian function suppression) in premenopausal breast cancer patients: ready for prime time?
Montagna E; Cancello G; Colleoni M
Cancer Treat Rev; 2013 Dec; 39(8):886-90. PubMed ID: 23725877
[TBL] [Abstract][Full Text] [Related]
6. Combined ovarian ablation and aromatase inhibition as first-line therapy for hormone receptor-positive metastatic breast cancer in premenopausal women: report of three cases.
El-Saghir NS; El-Hajj II; Makarem JA; Otrock ZK
Anticancer Drugs; 2006 Sep; 17(8):999-1002. PubMed ID: 16940812
[TBL] [Abstract][Full Text] [Related]
7. [Tamoxifen and aromatase inhibitors in the treatment of breast cancer in menopausal women: pharmacological and clinical aspects].
de Cremoux P; Diéras V; Poupon MF; Magdelénat H; Sigal-Zafrani B; Fourquet A; Pierga JY
Bull Cancer; 2004 Dec; 91(12):917-27. PubMed ID: 15634633
[TBL] [Abstract][Full Text] [Related]
8. [Treatment with Aromatase Inhibitors in Postmenopausal Women with Breast Cancer and the Possibility of Influencing Side Effects].
Krásenská M
Klin Onkol; 2016; 29 Suppl 3():S39-49. PubMed ID: 28118723
[TBL] [Abstract][Full Text] [Related]
9. Aromatase inhibitor plus ovarian suppression as adjuvant therapy in premenopausal women with breast cancer.
Figg WD; Cook K; Clarke R
Cancer Biol Ther; 2014; 15(12):1586-7. PubMed ID: 25535893
[TBL] [Abstract][Full Text] [Related]
10. Complete estrogen blockade for the treatment of metastatic and early stage breast cancer.
Michaud LB; Buzdar AU
Drugs Aging; 2000 Apr; 16(4):261-71. PubMed ID: 10874521
[TBL] [Abstract][Full Text] [Related]
11. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
Carpenter R
Eur J Surg Oncol; 2008 Jul; 34(7):746-55. PubMed ID: 18296017
[TBL] [Abstract][Full Text] [Related]
12. Luteininzing hormone releasing hormones analogs in combination with tamoxifen for the adjuvant treatment of premenopausal women with hormone receptor positive breast cancer.
Conte B; Poggio F; Del Mastro L
Expert Opin Pharmacother; 2017 Sep; 18(13):1357-1362. PubMed ID: 28764603
[TBL] [Abstract][Full Text] [Related]
13. Aromatase inhibitors and breast cancer.
Miller WR
Minerva Endocrinol; 2006 Mar; 31(1):27-46. PubMed ID: 16498362
[TBL] [Abstract][Full Text] [Related]
14. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.
Gibson L; Lawrence D; Dawson C; Bliss J
Cochrane Database Syst Rev; 2009 Oct; 2009(4):CD003370. PubMed ID: 19821307
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant endocrine therapy of perimenopausal and recently postmenopausal women with hormone receptor-positive breast cancer.
Pan K; Chlebowski RT
Clin Breast Cancer; 2014 Jun; 14(3):147-53. PubMed ID: 24503025
[TBL] [Abstract][Full Text] [Related]
16. Luteinizing hormone-releasing hormone agonists in premenopausal hormone receptor-positive breast cancer.
Tan SH; Wolff AC
Clin Breast Cancer; 2007 Feb; 7(6):455-64. PubMed ID: 17386122
[TBL] [Abstract][Full Text] [Related]
17. Optimizing the use of aromatase inhibitors in adjuvant therapy for postmenopausal patients with hormone-responsive early breast cancer: current and future prospects.
Jonat W; Hilpert F
J Cancer Res Clin Oncol; 2006 Jun; 132(6):343-55. PubMed ID: 16450161
[TBL] [Abstract][Full Text] [Related]
18. Sequencing of endocrine therapies in breast cancer--integration of recent data.
Carlson RW
Breast Cancer Res Treat; 2002 Oct; 75 Suppl 1():S27-32; discussion S33-5. PubMed ID: 12353821
[TBL] [Abstract][Full Text] [Related]
19. Exemestane as first-line therapy in postmenopausal women with recurrent or metastatic breast cancer.
Glück S
Am J Clin Oncol; 2010 Jun; 33(3):314-9. PubMed ID: 19730353
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant endocrine therapy for premenopausal women with hormone-responsive breast cancer.
Mathew A; Davidson NE
Breast; 2015 Nov; 24 Suppl 2():S120-5. PubMed ID: 26255743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
